查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1555486

亨廷顿氏舞蹈症治疗市场，按诊断类型、治疗类型、药物类型、最终用户、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Huntington's Disease Treatment Market, By Diagnosis Type, By Treatment Type, By Drug Type, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 284 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年亨丁顿舞蹈症治疗市场规模为4.509亿美元，2024年至2032年复合年增长率为24.10%。

亨丁顿舞蹈症治疗市场-市场动态

亨廷顿病病例的激增以及对治疗该疾病的尖端药物的需求不断增加预计将推动市场成长

对亨丁顿舞蹈症的了解不断增加，加上诊断工具的进步，使得早期识别和介入成为可能，从而导致对治疗选择的需求增加。这种大脑退化性疾病影响每 10 万人中约 3 至 7 人，主要是欧洲血统的人。製药公司和研究机构正在投入大量资源进行研发，以发现新的治疗方案并改善现有疗法，从而推动市场的成长。此外，药物研究的进步为市场扩张提供了更多可能性。然而，发展中地区缺乏认识可能会阻碍市场的进步。

亨廷顿舞蹈症治疗市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 24.10% 左右的复合年增长率成长

根据诊断类型细分，预计诊断成像将在 2023 年显示最大的市场份额

根据治疗类型细分，2023年对症治疗为主导类型

根据药物类型细分，丁苯那嗪是 2023 年的主导类型

根据最终用户细分，医院药局是 2023 年的主导类型

按地区划分，北美是 2023 年的主要收入来源

亨廷顿舞蹈症治疗市场-細項分析：

全球亨廷顿舞蹈症治疗市场根据诊断类型、治疗类型、药物类型、最终用户和地区进行细分。

根据诊断类型，市场分为两类：诊断影像、基因检测和其他。诊断成像占据最大的市场份额。由于技术进步提高了诊断、监测和治疗效果评估的精确度，亨廷顿舞蹈症治疗市场的诊断影像领域正在不断进步。

根据治疗类型，市场分为两类：症状治疗、疾病缓解治疗和其他。对症治疗占市场大部分。症状治疗市场包括一系列旨在控制 HD 各种症状的方法和治疗，例如运动功能障碍、精神症状和认知能力下降。

根据药物类型，市场分为两类：丁苯那嗪、丁苯那嗪和其他药物。丁苯那嗪占有最大的市场份额。丁苯那嗪主要用于治疗舞蹈病，这是亨廷顿舞蹈症的一种常见且致残的症状。舞蹈病的特征是不自主的、突然的运动，会大大影响日常活动和运动。

根据最终用户，市场分为三类：医院药房、零售药房和线上药房。医院药房是市场的主导部门。他们在药物管理、配药、患者护理和治疗支持方面发挥着至关重要的作用。

亨廷顿舞蹈症治疗市场 - 地理洞察

从地理上看，该市场横跨北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些区域根据对商业活动有贡献的国家进一步细分。在疾病缓解疗法需求不断增长的推动下，北美引领市场。该地区拥有多家着名的製药和生物技术公司，这些公司积极参与亨廷顿病疾病缓解疗法的研究和开发。根据国家卫生统计中心的数据，2019年，19.2%的成年人在过去12个月内接受过某种形式的心理健康治疗，其中15.8%使用处方药，9.5%接受心理健康专业人士的咨询或治疗。由于意识的提高和早期诊断，欧洲成为市场成长的第二大地区。

亨廷顿舞蹈症治疗市场-竞争格局：

製造商正集中精力在开发疾病缓解疗法和创新对症疗法方面进行大量研发投资。公司和研究机构正在探索各种方法，例如神经保护剂和先进的基因编辑技术。许多公司正在进行测试新药和治疗策略的临床试验，导致下一代 HD 疗法的竞争。提供全面的患者支持计划（包括咨询和教育）的公司可以透过提高患者的依从性和满意度来获得竞争优势。

最新进展：

A recent interim update on the phase 1/2 trials for uniQure's experimental gene therapy AMT-130 revealed that administering high doses of the treatment led to a notable deceleration of disease advancement and reduction of neurofilament light (NfL) levels in individuals with Huntington's disease (高画质).

目录

第一章：亨廷顿舞蹈症治疗市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 亨丁顿舞蹈症治疗市场片段（依诊断类型）
    • 亨丁顿舞蹈症治疗市场片段（依治疗类型）
    • 亨丁顿舞蹈症治疗市场片段（依药物类型）
    • 最终用户的亨丁顿舞蹈症治疗市场片段
    • 亨丁顿舞蹈症治疗市场片段（按国家/地区）
    • 按地区分類的亨丁顿舞蹈症治疗市场片段
  • 竞争洞察

第 3 章：亨廷顿舞蹈症治疗主要市场趋势

  • 亨丁顿舞蹈症治疗市场驱动因素
    • 市场驱动因素的影响分析
  • 亨丁顿舞蹈症治疗市场限制
    • 市场限制影响分析
  • 亨丁顿舞蹈症治疗市场机会
  • 亨丁顿舞蹈症治疗市场未来趋势

第 4 章：亨廷顿舞蹈症治疗产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：亨廷顿舞蹈症治疗市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：亨廷顿氏症治疗市场格局

  • 亨廷顿舞蹈症治疗市场占有率分析，2023 年
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：亨廷顿氏症治疗市场 - 依诊断类型

  • 概述
    • 按诊断类型分類的细分市场份额分析
    • 诊断影像
    • 基因检测
    • 其他的

第 8 章：亨廷顿氏症治疗市场 - 按治疗类型

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 症状治疗
    • 疾病缓解疗法
    • 其他的

第 9 章：亨廷顿氏症治疗市场 - 按药物类型

  • 概述
    • 按药物类型分類的细分市场份额分析
    • 丁苯那嗪
    • 丁苯那嗪
    • 其他药物

第 10 章：亨廷顿舞蹈症治疗市场 - 按最终用户

  • 概述
    • 按最终用户分類的细分市场占有率分析
    • 医院药房
    • 零售药局
    • 网路药局

第 11 章：亨廷顿氏症治疗市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美亨廷顿舞蹈症治疗主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按诊断类型）
    • 北美市场规模和预测（按治疗类型）
    • 北美市场规模和预测（按药物类型）
    • 北美市场规模和预测（按最终用户）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲亨廷顿舞蹈症治疗主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模和预测（按诊断类型）
    • 欧洲市场规模和预测（按治疗类型）
    • 欧洲市场规模和预测（按药物类型）
    • 欧洲市场规模和预测（按最终用户）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区亨廷顿舞蹈症治疗主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模和预测（按诊断类型）
    • 亚太地区市场规模与预测（按治疗类型）
    • 亚太地区市场规模和预测（按药物类型）
    • 亚太地区市场规模和预测（按最终用户）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲亨廷顿舞蹈症治疗主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模和预测（按诊断类型）
    • 拉丁美洲市场规模与预测（按治疗类型）
    • 拉丁美洲市场规模与预测（按药物类型）
    • 拉丁美洲市场规模和预测（按最终用户）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲亨廷顿氏舞蹈症治疗主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模及预测（按诊断类型）
    • 中东和非洲市场规模及预测（按治疗类型）
    • 中东和非洲市场规模及预测（按药物类型）
    • 中东和非洲市场规模和预测（按最终用户）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 12 章：主要供应商分析 - 亨廷顿舞蹈症治疗产业

  • 竞争仪表板
  • 公司简介
    • Pfizer Inc.
    • Alnylam Pharmaceuticals Inc.
    • Ceregene Inc.
    • Prana Biotechnology Limited
    • Teva Pharmaceutical Industries Ltd
    • Ionis Pharmaceuticals
    • Neurocrine Biosciences Inc.
    • Prilenia Therapeutics
    • Azevan Pharmaceuticals
    • Lundbeck
    • PTC Therapeutics
    • UniQure
    • Others

第 13 章：360 度分析师视角

第 14 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV3593

REPORT HIGHLIGHT

Huntington's Disease Treatment Market size was valued at USD 450.90 million in 2023, expanding at a CAGR of 24.10% from 2024 to 2032.

Huntington's disease is a rare genetic disorder that currently has no cure and causes the deterioration of brain cells. Early signs often include problems with coordination and occasional memory lapses. This disease has a significant impact on a person's motor skills, cognitive functions, and overall mental health. The rarity of Huntington's disease is notable, as it is usually passed down through a mutated gene from one of the parents. The disorder mainly results in a range of movement difficulties, as well as mental health challenges and issues with cognitive processes like planning and reasoning. According to the Genetic and Rare Diseases Information Center (GARD), there are fewer than 5,000 individuals in the United States living with Huntington's disease.

Huntington's Disease Treatment Market- Market Dynamics

The surge in Huntington's disease cases and the escalating requirement for cutting-edge drugs to address the disease are projected to fuel market growth

Increased knowledge about Huntington's disease, along with advancements in diagnostic tools, is enabling early identification and intervention, leading to a rise in the need for treatment choices. This degenerative brain condition affects around 3 to 7 people per 100,000, mainly in individuals of European ancestry. Pharmaceutical companies and research institutions are dedicating significant resources to research and development to discover new treatment options and improve existing therapies, thereby fueling the growth of the market. Furthermore, advancements in drug research offer additional possibilities for market expansion. However, a lack of awareness in developing areas could impede the progress of the market.

Huntington's Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 24.10% over the forecast period (2024-2032)

Based on Diagnosis Type segmentation, Diagnostic Imaging was predicted to show maximum market share in the year 2023

Based on Treatment Type segmentation, Symptomatic Therapy was the leading type in 2023

Based on Drug Type segmentation, Tetrabenazine was the leading type in 2023

Based on End-User segmentation, Hospital Pharmacies was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Huntington's Disease Treatment Market- Segmentation Analysis:

The Global Huntington's Disease Treatment Market is segmented based on Diagnosis Type, Treatment Type, Drug Type, End-User, and Region.

The market is categorized into two groups according to Diagnosis Type: Diagnostic Imaging, Genetic Testing, and Others. Diagnostic Imaging holds the largest share of the market. The diagnostic imaging sector of Huntington's disease Treatment Market is progressing due to technological advancements that enhance the precision of diagnosis, monitoring, and assessment of treatment effectiveness.

The market is segmented into two categories according to Treatment Type: Symptomatic Therapy, Disease-Modifying Therapy, and Others. Symptomatic Therapy holds the majority share in the market. The market for symptomatic therapy treatment encompasses a range of methods and treatments aimed at managing the various symptoms of HD, such as motor dysfunction, psychiatric symptoms, and cognitive decline.

The market is segmented into two groups according to Drug Type: Tetrabenazine, Deutetrabenazine, and Other Drugs. Tetrabenazine holds the largest share of the market. Tetrabenazine is mainly prescribed for the treatment of chorea, a prevalent and disabling symptom of Huntington's disease. Chorea is characterized by involuntary, abrupt movements that can greatly affect everyday activities and movement.

The market is segmented into three categories according to End-User: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. Hospital Pharmacies are the leading sector in the market. They play a vital role in medication management, dispensing, patient care, and treatment support.

Huntington's Disease Treatment Market- Geographical Insights

Geographically, this market spans across North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented by countries contributing to business activities. North America leads the market, driven by the increasing demand for disease-modifying therapies. This region is home to several prominent pharmaceutical and biotechnology companies actively involved in the research and development of disease-modifying therapies for Huntington's disease. According to the National Center for Health Statistics, in 2019, 19.2% of adults had received some form of mental health treatment in the past 12 months, with 15.8% using prescription medication and 9.5% receiving counseling or therapy from a mental health professional. Europe is the second-largest region for market growth, attributed to rising awareness and early diagnosis.

Huntington's Disease Treatment Market- Competitive Landscape:

Manufacturers are concentrating on making significant R&D investments in the development of disease-modifying treatments and innovative symptomatic therapies. Various approaches, such as neuroprotective agents and advanced gene-editing techniques, are being explored by companies and research institutions. Clinical trials to test new drugs and treatment strategies are being conducted by many companies, leading to competition in the advancement of the next generation of HD therapies. Companies that provide comprehensive patient support programs, including counseling and education, may gain a competitive advantage by improving patient adherence and satisfaction.

Recent Developments:

A recent interim update on the phase 1/2 trials for uniQure's experimental gene therapy AMT-130 revealed that administering high doses of the treatment led to a notable deceleration of disease advancement and reduction of neurofilament light (NfL) levels in individuals with Huntington's disease (HD).

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ceregene Inc.
  • Prana Biotechnology Limited
  • Teva Pharmaceutical Industries Ltd
  • Ionis Pharmaceuticals
  • Neurocrine Biosciences Inc.
  • Prilenia Therapeutics
  • Azevan Pharmaceuticals
  • Lundbeck
  • PTC Therapeutics
  • UniQure
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DIAGNOSIS TYPE- MARKET ANALYSIS, 2019 - 2032

  • Diagnostic Imaging
  • Genetic Testing
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Symptomatic Therapy
  • Disease-Modifying Therapy
  • Others

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Tetrabenazine
  • Deutetrabenazine
  • Other Drugs

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL HUNTINGTON'S DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Huntington's Disease Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Huntington's Disease Treatment Market Snippet by Diagnosis Type
    • 2.1.2. Huntington's Disease Treatment Market Snippet by Treatment Type
    • 2.1.3. Huntington's Disease Treatment Market Snippet by Drug Type
    • 2.1.4. Huntington's Disease Treatment Market Snippet by End-User
    • 2.1.5. Huntington's Disease Treatment Market Snippet by Country
    • 2.1.6. Huntington's Disease Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Huntington's Disease Treatment Key Market Trends

  • 3.1. Huntington's Disease Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Huntington's Disease Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Huntington's Disease Treatment Market Opportunities
  • 3.4. Huntington's Disease Treatment Market Future Trends

4. Huntington's Disease Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Huntington's Disease Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Huntington's Disease Treatment Market Landscape

  • 6.1. Huntington's Disease Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Huntington's Disease Treatment Market - By Diagnosis Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Diagnosis Type, 2023 & 2032 (%)
    • 7.1.2. Diagnostic Imaging
    • 7.1.3. Genetic Testing
    • 7.1.4. Others

8. Huntington's Disease Treatment Market - By Treatment Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment Type, 2023 & 2032 (%)
    • 8.1.2. Symptomatic Therapy
    • 8.1.3. Disease-Modifying Therapy
    • 8.1.4. Others

9. Huntington's Disease Treatment Market - By Drug Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 9.1.2. Tetrabenazine
    • 9.1.3. Deutetrabenazine
    • 9.1.4. Other Drugs

10. Huntington's Disease Treatment Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2023 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Huntington's Disease Treatment Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Huntington's Disease Treatment Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Huntington's Disease Treatment Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Huntington's Disease Treatment Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Huntington's Disease Treatment Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Huntington's Disease Treatment Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Diagnosis Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Huntington's Disease Treatment Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Pfizer Inc.
    • 12.2.2. Alnylam Pharmaceuticals Inc.
    • 12.2.3. Ceregene Inc.
    • 12.2.4. Prana Biotechnology Limited
    • 12.2.5. Teva Pharmaceutical Industries Ltd
    • 12.2.6. Ionis Pharmaceuticals
    • 12.2.7. Neurocrine Biosciences Inc.
    • 12.2.8. Prilenia Therapeutics
    • 12.2.9. Azevan Pharmaceuticals
    • 12.2.10. Lundbeck
    • 12.2.11. PTC Therapeutics
    • 12.2.12. UniQure
    • 12.2.13. Others

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us